You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Establishing Better Standards of Practice: Maximizing Patient Outcomes With Noninvasive Screening in Nonalcoholic Fatty Liver Disease

  • Authors: Mazen Noureddin, MD, MHSc; Jörn Schattenberg, MD; Naim Alkhouri, MD, FAASLD
  • CME / ABIM MOC Released: 1/20/2023
  • Valid for credit through: 1/20/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, diabetologists, and endocrinologists.

The goal of this activity is for learners to be better able to highlight the rationale for liver fibrosis screening and the role of noninvasive tests that can be used to assess the risk in clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Importance of risk assessment for liver fibrosis
    • Benefits of invasive and noninvasive testing
  • Have greater competence related to
    • Implementing noninvasive tests for liver fibrosis
  • Demonstrate greater confidence in their ability to
    • Implement noninvasive screening for liver fibrosis in clinical practice


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • Mazen Noureddin, MD, MHSc

    Houston Research Institute
    Houston, Texas, United States


    Mazen Noureddin, MD, MHSc, has the following relevant financial relationships:
    Consultant or advisor for: 89Bio; Altimmune; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; EchoSens; Gilead Sciences; GlaxoSmithKline; Merck; Novo Nordisk; OWL; Pfizer; Roche Diagnostics; Siemens; Terns; Takeda
    Research funding from: Akero; Allergan; Bristol Myers Squibb Company; Conatus; Corcept; Enanta; Galectin Therapeutics; Genfit; Gilead Sciences; Madrigal Pharmaceuticals; Novartis; Novo Nordisk; Shire; Terns; Viking Therapeutics; Zydus Pharmaceuticals
    Stock options from: Anaetos; ChronWell; CIMA; Rivus Pharma; Viking Therapeutics


  • Jörn Schattenberg, MD

    Professor of Medicine
    Metabolic Liver Research Program
    Department of Medicine
    University Medical Center Mainz
    Mainz, Germany


    Jörn Schattenberg, MD, has the following relevant financial relationships:
    Consultant or advisor for: Albireo Pharma Inc; Apollo Endosurgery; Bayer; Bristol Myers Squibb Company; Boehringer Ingelheim; Gilead Sciences; GlaxoSmithKline; Intercept Pharmaceuticals; Inventiva Pharma; Ipsen; Madrigal Pharmaceuticals; Merck Sharp & Dohme; Northsea Therapeutics; Novartis; Novo Nordisk; Pfizer; Roche; Sanofi; Siemens Healthcare GmbH
    Speaker or member of speakers bureau for: Boehringer Ingelheim; Echosens; Madrigal Pharmaceuticals; MedPublico GmbH; Novo Nordisk
    Research funding from: Boehringer Ingelheim; Gilead Sciences; Siemens Healthcare GmbH

  • Naim Alkhouri, MD, FAASLD

    Chief of Transplant Hepatology
    Fatty Liver Program
    Arizona Liver Health (ALH)
    Phoenix, Arizona, United States


    Naim Alkhouri, MD, FAASLD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie/Allergan; Echosens; Fibronostics; Gilead Sciences; Intercept Pharmaceuticals; Madrigal Pharmaceuticals; Novo Nordisk; Perspectum; Pfizer; Zydus Pharmaceuticals
    Speaker or member of speakers bureau for: AbbVie; Alexion; Echosens; Eisai; Exelixis; Gilead Sciences; Intercept; Perspectum; Salix; Siemens; Theratechnologies
    Research funding from: AbbVie/Allergan; Akero; Better Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb; Corcept; DSM; Galectin Therapeutics; Genentech; Genfit; Gilead Sciences; Healio; Hepagene Therapeutics; Intercept Pharmaceuticals; Inventiva Pharma; Ionis; Madrigal Pharmaceuticals; Merck; NGM Biopharmaceuticals; Noom; NorthSea; Novo Nordisk; Perspectum; Pfizer; Poxel; Viking Therapeutics; Zydus Pharmaceuticals


  • Anne G. Le, PharmD

    Senior Medical Education Director, Medscape, LLC


    Anne G. Le, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Establishing Better Standards of Practice: Maximizing Patient Outcomes With Noninvasive Screening in Nonalcoholic Fatty Liver Disease

Authors: Mazen Noureddin, MD, MHSc; Jörn Schattenberg, MD; Naim Alkhouri, MD, FAASLDFaculty and Disclosures

CME / ABIM MOC Released: 1/20/2023

Valid for credit through: 1/20/2024


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print